Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

GEVO vs VERO vs INMD vs AMTX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GEVO
Gevo, Inc.

Chemicals - Specialty

Basic MaterialsNASDAQ • US
Market Cap$493M
5Y Perf.+57.4%
VERO
Venus Concept Inc.

Medical - Devices

HealthcareNASDAQ • CA
Market Cap$499K
5Y Perf.-99.9%
INMD
InMode Ltd.

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$882M
5Y Perf.-5.0%
AMTX
Aemetis, Inc.

Oil & Gas Refining & Marketing

EnergyNASDAQ • US
Market Cap$213M
5Y Perf.+290.0%

GEVO vs VERO vs INMD vs AMTX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GEVO logoGEVO
VERO logoVERO
INMD logoINMD
AMTX logoAMTX
IndustryChemicals - SpecialtyMedical - DevicesMedical - DevicesOil & Gas Refining & Marketing
Market Cap$493M$499K$882M$213M
Revenue (TTM)$174M$59M$375M$209M
Net Income (TTM)$-11M$-55M$87M$-74M
Gross Margin23.4%64.4%77.8%3.4%
Operating Margin-4.6%-59.0%21.3%-13.4%
Forward P/E9.6x
Total Debt$168M$43M$13M$318M
Cash & Equiv.$1M$4M$303M$5M

GEVO vs VERO vs INMD vs AMTXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GEVO
VERO
INMD
AMTX
StockMay 20May 26Return
Gevo, Inc. (GEVO)100157.4+57.4%
Venus Concept Inc. (VERO)1000.1-99.9%
InMode Ltd. (INMD)10095.0-5.0%
Aemetis, Inc. (AMTX)100390.0+290.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: GEVO vs VERO vs INMD vs AMTX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INMD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Gevo, Inc. is the stronger pick specifically for growth and revenue expansion. AMTX also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
GEVO
Gevo, Inc.
The Growth Play

GEVO is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
  • 8.5% revenue growth vs AMTX's -22.3%
Best for: growth exposure
VERO
Venus Concept Inc.
The Secondary Option

VERO lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
INMD
InMode Ltd.
The Income Pick

INMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • beta 1.04
  • 105.0% 10Y total return vs AMTX's 31.1%
  • Lower volatility, beta 1.04, Low D/E 1.9%, current ratio 9.88x
  • Beta 1.04, current ratio 9.88x
Best for: income & stability and long-term compounding
AMTX
Aemetis, Inc.
The Momentum Pick

AMTX is the clearest fit if your priority is momentum.

  • +140.0% vs VERO's -88.5%
Best for: momentum
See the full category breakdown
CategoryWinnerWhy
GrowthGEVO logoGEVO8.5% revenue growth vs AMTX's -22.3%
Quality / MarginsINMD logoINMD23.3% margin vs VERO's -92.8%
Stability / SafetyINMD logoINMDBeta 1.04 vs GEVO's 1.64, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)AMTX logoAMTX+140.0% vs VERO's -88.5%
Efficiency (ROA)INMD logoINMD11.8% ROA vs VERO's -88.6%, ROIC 13.5% vs -39.8%

GEVO vs VERO vs INMD vs AMTX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GEVOGevo, Inc.
FY 2025
Ethanol
95.6%$105M
Hydrocarbon
4.4%$5M
VEROVenus Concept Inc.
FY 2024
System
58.6%$38M
Leases
20.5%$13M
Product
16.1%$10M
Service
4.7%$3M
INMDInMode Ltd.
FY 2025
Capital Equipment
100.0%$289M
AMTXAemetis, Inc.
FY 2025
Ethanol Sales
79.4%$116M
Wet Distiller's Grains Sales
20.6%$30M

GEVO vs VERO vs INMD vs AMTX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINMDLAGGINGAMTX

Income & Cash Flow (Last 12 Months)

INMD leads this category, winning 4 of 6 comparable metrics.

INMD is the larger business by revenue, generating $375M annually — 6.4x VERO's $59M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to VERO's -92.8%. On growth, GEVO holds the edge at +47.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGEVO logoGEVOGevo, Inc.VERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AMTX logoAMTXAemetis, Inc.
RevenueTrailing 12 months$174M$59M$375M$209M
EBITDAEarnings before interest/tax$18M-$31M$81M-$21M
Net IncomeAfter-tax profit-$11M-$55M$87M-$74M
Free Cash FlowCash after capex-$35M-$21M$91M-$38M
Gross MarginGross profit ÷ Revenue+23.4%+64.4%+77.8%+3.4%
Operating MarginEBIT ÷ Revenue-4.6%-59.0%+21.3%-13.4%
Net MarginNet income ÷ Revenue-6.6%-92.8%+23.3%-35.4%
FCF MarginFCF ÷ Revenue-19.9%-35.2%+24.2%-18.2%
Rev. Growth (YoY)Latest quarter vs prior year+47.5%-8.2%+5.3%+27.4%
EPS Growth (YoY)Latest quarter vs prior year+3.8%-8.5%-30.8%+29.8%
INMD leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

VERO leads this category, winning 2 of 4 comparable metrics.

On an enterprise value basis, INMD's 6.9x EV/EBITDA is more attractive than GEVO's 102.1x.

MetricGEVO logoGEVOGevo, Inc.VERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AMTX logoAMTXAemetis, Inc.
Market CapShares × price$493M$498,989$882M$213M
Enterprise ValueMkt cap + debt − cash$659M$39M$593M$526M
Trailing P/EPrice ÷ TTM EPS-14.50x-0.00x9.73x-2.44x
Forward P/EPrice ÷ next-FY EPS est.9.64x
PEG RatioP/E ÷ EPS growth rate0.98x
EV / EBITDAEnterprise value multiple102.12x6.88x
Price / SalesMarket cap ÷ Revenue3.07x0.01x2.38x1.02x
Price / BookPrice ÷ Book value/share1.01x0.07x1.33x
Price / FCFMarket cap ÷ FCF10.46x
VERO leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

INMD leads this category, winning 7 of 9 comparable metrics.

INMD delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-17 for VERO. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to VERO's 15.16x. On the Piotroski fundamental quality scale (0–9), VERO scores 5/9 vs INMD's 3/9, reflecting solid financial health.

MetricGEVO logoGEVOGevo, Inc.VERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AMTX logoAMTXAemetis, Inc.
ROE (TTM)Return on equity-2.4%-17.4%+13.3%
ROA (TTM)Return on assets-1.7%-88.6%+11.8%-29.3%
ROICReturn on invested capital-2.8%-39.8%+13.5%-70.3%
ROCEReturn on capital employed-3.1%-54.2%+12.1%-19.0%
Piotroski ScoreFundamental quality 0–94534
Debt / EquityFinancial leverage0.36x15.16x0.02x
Net DebtTotal debt minus cash$166M$39M-$289M$313M
Cash & Equiv.Liquid assets$1M$4M$303M$5M
Total DebtShort + long-term debt$168M$43M$13M$318M
Interest CoverageEBIT ÷ Interest expense-0.04x-9.69x-0.27x
INMD leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — GEVO and INMD and AMTX each lead in 2 of 6 comparable metrics.

A $10,000 investment in INMD five years ago would be worth $3,613 today (with dividends reinvested), compared to $9 for VERO. Over the past 12 months, AMTX leads with a +140.0% total return vs VERO's -88.5%. The 3-year compound annual growth rate (CAGR) favors GEVO at 18.2% vs VERO's -79.4% — a key indicator of consistent wealth creation.

MetricGEVO logoGEVOGevo, Inc.VERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AMTX logoAMTXAemetis, Inc.
YTD ReturnYear-to-date-1.5%-82.3%-5.9%+96.2%
1-Year ReturnPast 12 months+88.0%-88.5%-2.1%+140.0%
3-Year ReturnCumulative with dividends+65.0%-99.1%-60.2%+37.4%
5-Year ReturnCumulative with dividends-65.2%-99.9%-63.9%-76.1%
10-Year ReturnCumulative with dividends-98.6%-100.0%+105.0%+31.1%
CAGR (3Y)Annualised 3-year return+18.2%-79.4%-26.4%+11.2%
Evenly matched — GEVO and INMD and AMTX each lead in 2 of 6 comparable metrics.

Risk & Volatility

INMD leads this category, winning 2 of 2 comparable metrics.

INMD is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than GEVO's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INMD currently trades 83.2% from its 52-week high vs VERO's 2.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGEVO logoGEVOGevo, Inc.VERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AMTX logoAMTXAemetis, Inc.
Beta (5Y)Sensitivity to S&P 5001.64x1.43x1.04x1.46x
52-Week HighHighest price in past year$2.97$12.93$16.74$3.80
52-Week LowLowest price in past year$1.01$0.26$12.72$1.22
% of 52W HighCurrent price vs 52-week peak+68.4%+2.1%+83.2%+82.1%
RSI (14)Momentum oscillator 0–10053.542.939.858.2
Avg Volume (50D)Average daily shares traded4.5M9K804K1.8M
INMD leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: GEVO as "Buy", INMD as "Buy", AMTX as "Buy". Consensus price targets imply 72.4% upside for GEVO (target: $4) vs -43.9% for AMTX (target: $2).

MetricGEVO logoGEVOGevo, Inc.VERO logoVEROVenus Concept Inc.INMD logoINMDInMode Ltd.AMTX logoAMTXAemetis, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$3.50$16.00$1.75
# AnalystsCovering analysts14117
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+14.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

INMD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VERO leads in 1 (Valuation Metrics). 1 tied.

Best OverallInMode Ltd. (INMD)Leads 3 of 6 categories
Loading custom metrics...

GEVO vs VERO vs INMD vs AMTX: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is GEVO or VERO or INMD or AMTX a better buy right now?

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -22. 3% for Aemetis, Inc. (AMTX). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Gevo, Inc. (GEVO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — GEVO or VERO or INMD or AMTX?

Over the past 5 years, InMode Ltd.

(INMD) delivered a total return of -63. 9%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: INMD returned +105. 0% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — GEVO or VERO or INMD or AMTX?

By beta (market sensitivity over 5 years), InMode Ltd.

(INMD) is the lower-risk stock at 1. 04β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 58% more volatile than INMD relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — GEVO or VERO or INMD or AMTX?

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -22. 3% for Aemetis, Inc. (AMTX). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — GEVO or VERO or INMD or AMTX?

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -41. 9% for VERO. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is GEVO or VERO or INMD or AMTX more undervalued right now?

Analyst consensus price targets imply the most upside for GEVO: 72.

4% to $3. 50.

07

Which pays a better dividend — GEVO or VERO or INMD or AMTX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is GEVO or VERO or INMD or AMTX better for a retirement portfolio?

For long-horizon retirement investors, InMode Ltd.

(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +105. 0% 10Y return). Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INMD: +105. 0%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between GEVO and VERO and INMD and AMTX?

These companies operate in different sectors (GEVO (Basic Materials) and VERO (Healthcare) and INMD (Healthcare) and AMTX (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GEVO is a small-cap high-growth stock; VERO is a small-cap quality compounder stock; INMD is a small-cap deep-value stock; AMTX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

GEVO

High-Growth Disruptor

  • Sector: Basic Materials
  • Market Cap > $100B
  • Revenue Growth > 23%
  • Gross Margin > 14%
Run This Screen
Stocks Like

VERO

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 38%
Run This Screen
Stocks Like

INMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 13%
Run This Screen
Stocks Like

AMTX

High-Growth Disruptor

  • Sector: Energy
  • Market Cap > $100B
  • Revenue Growth > 13%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GEVO and VERO and INMD and AMTX on the metrics below

Revenue Growth>
%
(GEVO: 47.5% · VERO: -8.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.